1. Jadvar, H, Xu, A, Tumeh, P, Pollock, J, Nezami, M, Conti, P, Surveillance and Management of Lymphoma with Serial FDG PET-CT.  Radiological Society of North America 2005 Scientific Assembly and Annual Meeting, November 27 - December 2, 2005 ,Chicago IL
  2. http://archive.rsna.org/2005/4407297.html

  3. Nezami, M. A., Stobbe, D., Gould-Simon, A. (2014) Angiogenesis: cause or effect? Companion diagnostics and surrogate markers for a novel antiangiogenic therapy multitargeted epigenetic therapies (MTET). The Free Library.
    http://www.thefreelibrary.com/Angiogenesis%3a+cause+or+effect%3f+Companion+diagnostics+and+surrogate...-a0427757449
  4. Nezami, M. A., Stobbe, D., Gould-Simon, A. (2015). Prognostic surrogate markers for survival, a case series for a novel antiangiogenic therapy (multitargeted epigenetic therapies/MTET). Pancreatic Cancer Symposium, POSTER A39.

    http://pcs-2015.com/files/110/comm/posters/a39-.pdf

  5. Nezami, M. A., Stobbe, D., Gould-Simon, A., & Hager, S. (2015). Abstract C140: Heterogenous approach for heterogenous disease, heterogeneity in cancer genomics and epigenetic approach. Molecular Cancer Therapeutics, 14(12 Supplement 2). http://scientonline.org/open-access/heterogenous-approach-for-heterogenous-disease-heterogeneity-in-cancer-genomics-and-epigenetic-approach.pdf
  6. Nezami, M., Gould-Simon, A., Stobbe, D., & Hager, S. (2015). 495PEpigenetic regulation of hypoxia and heterogeneity. Annals of Oncology, 26 (Suppl 9). http://annonc.oxfordjournals.org/content/26/suppl_9/ix151.3.ful
  7. Nezami, M., Hager, S., & Garner, J. (2015). EMT and Anti-EMT Strategies in Cancer. JCT Journal of Cancer Therapy, 1013-1019.
    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=60708
  8. Nezami, M., Hager, S., & Garner, J. (2015). Epigenetic therapies, immune therapies, and anti-angiogenic therapies: The triad of oncology. Angiogenesis: Cause or effect?. Journal of Precision Medicine, 43-48.

    http://www.thejournalofprecisionmedicine.com/wp-content/uploads/2015/12/NEZAMI1.pdf

  9. Nezami, M. A., Hager, S., & Lanman, R. (2015). Abstract B86: Impact of multi targeted epigenetic therapy (MTET): A series of 100 consecutive advanced solid tumor cancers. Molecular Cancer Therapeutics, 14(12 Supplement 2).
    http://mct.aacrjournals.org/content/14/12_Supplement_2/B86.short

  10. Nezami, M., Stobbe, D., & Hager, S. (2015). Abstract A122: Case review for multi-targeted epigenetic therapy (MTET) and its rationale in an integrative approach. Cancer Research, 75 (13 Supplement).
  11. Nezami M.A, Prognostic surrogates markers for survival, a case series for a novel antiangiogenic therapy( Multitargeted epigenetic therapy( MTET), 12th International Conference of the Society of Integrative Oncology ( SIO), november 12-14, 2015, Boston, massachutetts, https://integrativeonc.org/docman-library/events/conference-materials/182-sio2015-poster-abstracts/file
  12. Nezami, M., Hager, S., & Garner, J. (2016). The Role of Telomeres in Cancer Development and Progression, and the Double Edge Sword Effect with Tamoxifen. Biology and Medicine, 8:3.
    http://www.omicsonline.com/open-access/the-role-of-telomeres-in-cancer-development-and-progression-and-the-double-edge-sword-effect-with-tamoxifen-0974-8369-1000296.php?aid=7158
  13. Nezami, M., Hager, S., & Garner, J. (2016). Preliminary Findings on Multi-Targeted Epigenetic Therapy in Modifying Telomerase Activity. Cancer Science Open Access, 2:1:007.
    http://scientonline.org/open-access/preliminary-findings-on-multi-targeted-epigenetic-therapy-in-modifying-telomerase-activity.pdf
  14. Nezami, M., Hager, S., & Garner, J. (2016). Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi Targeted Epigenetic Therapy (MTET). JCT Journal of Cancer Therapy, 254-269.

    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=65475

  15. Nezami, M. A., Simon, A. G., & Bartholomeusz, G. (2016). Correlation of an ex Vivo Model with Clinical Application of an Epigenetic Modifier, Inhibiting Tumor Growth and Metastasis, in Resistant Cholangiocarcinoma—A Case Study. Journal of Cancer Therapy, 07(01), 50-54.
    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=63102

  16. Nezami, M. (2016). Chemoprevention and epigenetic multitargeted approach. Journal of Clinical Oncology, 2016 Cancer Survivorship Symposium: Advancing Care and Research, 34 (3 Supplement).
    http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/34/3_suppl/e297

  17. M.A. Nezami, Daniel Stobbe, Aaron Gould-Simon and Steven Hager, DOI: 10.1158/1535-7163.TARG-15-C140 Published December 2015 , Abstract C140: Herogenous approah for heterogenous disease, heterogeneity in cancer genomics and epigenetic approach
    http://mct.aacrjournals.org/content/14/12_Supplement_2/C140.short

  18. M.Nezami, Steven Hager, Richard Lanman Published December 2015, American Association for Cancer Research( AACR)
    Molecular Cancer Therapeutics,
    Abstract B86. Impact of multitargeted epigenetic therapy( MTET): a series of 100 consecutive advanced solid tumor cancers

    18. M.Nezami, " Epigenetic therapies and the use of multitargeted approach, A new concept in cancer therapeutics",
    J Cancer Sci Ther, November 2016, DOI: 10.4172/1948-5956.C1.093

    19. M.Nezami MD, "Biological interventions to interfere micronevironmental and endocrine machinery in cancer, " Application of endocrine manipulation in advanced cancer"
    J Cancer Sci Ther, November 2016, DOI: 10.4172/1948-5956.C1.093

    20. M.Nezami MD, Jessica Garner: Role of antiangiogenic therapy in prevention of recurrence in hormonal positive breast CA, A secondary prevention strategy and method of therapy, " Journal of Cancer Therapy, 6.2017, 8/546/552



    ....